Oruka Therapeutics reported mid-stage psoriasis results for ORKA-001, an IL-23 monoclonal antibody with long-acting potential. In a Phase 2 trial, Oruka said 40 of 63 patients achieved PASI 100 at 16 weeks, compared with 1 of 21 placebo recipients, and 83% reached PASI 90. The company also cited updated blood exposure analysis supporting a once-yearly dosing concept. Analysts framed the data as a potential differentiator against marketed IL-23 blockbusters that require multiple injections per year. The next key inflection will be late-stage confirmation of efficacy durability, safety, and dosing convenience in a patient population large enough to validate the exposure-response profile.